The ability of famciclovir and valaciclovirto affect the establishment and maintenance of latency in mice with a cutaneous herpes simplex type 1 (HSV-l) infection was examined. Mice were treated via drinking water starting at various times between days 1 and 5 and terminating on day 10 after inoculation. Clinical signs and viral replication in the target tissues were monitored. Three to four months later, trigeminal and dorsal root ganglia were explanted from groups of 16 mice and examined for latent virus by cocultivation. The two compounds differed in their effects on the acute neural infection, and ganglia explanted from famciclovir-treated mice were markedly reduced in their ability to reactivate virus, although neither drug affected latency if treatment was delayed for several months. The difference between the compounds is likely to reflect differencesin the metabolism of their respective products, penciclovir and acyclovir, in infected neurons.
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The ability to establish latent infections in the neurons of the peripheral nervous system is the hallmark of the alphaherpesviruses, of which herpes simplex virus (HSV) is by far the best studied [1, 2] . It is well understood that infection of the mucosal surfaces or skin site leads rapidly to the establishment of ganglionic infection. Herpesvirus particles have been shown to travel within axons in the retrograde direction at a rate of 2 mm/h [3] , and it is generally held that ganglia become infected within 24 h of exposure, although the rate of establishment of latent foci is also related to the dose of the inoculum [4] . Several animal models have been extensively used to study latent HSV infections, and the mouse ear infection is among these [4, 5] . The consensus is that nucleoside analogues (e.g., acyclovir) can reduce the establishment of latent foci when administered from the time of virus inoculation or very shortly thereafter [4, [6] [7] [8] [9] . However, it has been shown by many different studies that once established, latent infections are refractory to prolonged treatment with nucleoside analogues such as acyclovir [6, 9, 10] . Furthermore, studies in a rabbit ocular model, in which latent HSV can be repeatedly reactivated by means of epinephrine treatment, have demonstrated that acyclovir therapy could not cure latent infection [11] .
The present study concerns the comparative effects of famciclovir [12, 13] and valaciclovir [14, 15] on the establishment and reactivation of latent HSV -1 infection in mice. The two drugs are oral forms of penciclovir and acyclovir, respectively.
Previous results using the HSV-1 murine ear pinna model showed that famciclovir was superior to valaciclovir in terms of the amelioration of clinical signs and the reduction of infectious virus in both skin and nervous tissue when therapy was begun 1 day after virus inoculation [16] . Furthermore, both compounds were also found to be effective, even when the start of therapy was delayed until day 5 after inoculation [17] . In either case, after cessation of therapy during the acute phase of infection (after 5 days or 10 days of daily therapy), infectious virus reappeared in the target tissues of valaciclovir-but not famciclovir-treated animals. We have reported previously that the two compounds have similar antiviral activity in murine cells against the HSV-l strain used in this study [16] . Furthermore, famciclovir and valaciclovir generated very similar blood concentration-time curves for their respective products, penciclovir and acyclovir [16] . Thus, trivial explanations for the superior efficacy of famciclovir over valaciclovir were excluded. On completion of the studies of acute infections, a number of mice were kept for several weeks; then the ganglia were explanted and tested for the presence of latent infection. The results from these studies suggested that the incidence of latent infection was far less in famciclovir-treated mice than in those treated with valaciclovir or placebo (unpublished data). Thus, a comprehensive experiment using large groups of mice was done to substantiate these preliminary findings.
Methods
Virus strain and tissue culture. The virus used was HSV-l SCI6. This strain has been extensively characterized in mice [5] and has been used previously for studying antiviral compounds [4, 16, 18, 19] .
Mice and virus inoculation. A total of 680 female 4-week-old BALB/c mice (Bantin and Kingman, Kingston, UK) were inoculated into the left ear pinna with 10 5 pfu/ear HSV-l SC16 using previously published methods [16] . JID 1996; 173 (February) Measurement of clinical signs. Mice were assessed subjectively once daily and all signs noted. Skin thickness was measured daily in individual mice with an engineer's micrometer screw gauge as described [4] . Ear lesions were defined as one or more vesicles (visible to the naked eye), blisters, crusts, or scabs, but excluding erythema or swelling, which were recorded separately. Mice with a flaccid ear pinna that failed to respond to a gentle stimulus were recorded as showing ear paralysis.
Titration ofvirus in tissue samples. Tissue samples (ear pinna or brainstem) were obtained from 3 mice/group/time point. Each sample was homogenized and titrated for infectious virus on BHK-21 cells as described [16] . All samples were coded before titration and the plates were read blind.
Detection of virus in ganglia. Ganglia that are innervated by the ear pinna, left trigeminal ganglia, and left cervical dorsal root ganglia (Cll, Clll, and CIV pooled) were obtained from 8 mice/ group on day 8 after inoculation. Ganglia were placed in 0.5 mL of Eagle's MEM in 2-mL glass vials with loose lids. After being incubated for 5 days at 37SC in a 5% CO 2 atmosphere, the samples were individually ground in l-mL glass homogenizers. Each sample was subjected to I min of ultrasonic vibration in an ice bath before being spun at slow speed to remove debris. Then, 0.2-mL samples of the neat supernatant and 0.5 mL of a I: 10 dilution were inoculated onto BHK-21 cell monolayers. Cell cultures were examined after 48 h of incubation and the results recorded. However, all plates were incubated for at least 14 days after inoculation with fresh medium for the late appearance of cytopathic effect. Samples were coded before testing and read blind.
Isolation oflatent virus from ganglia. Groups of 16 mice were kept for 4 months after inoculation to study latency. Mice were killed, a few at a time, over 5-6 weeks (days 106-144 after inoculation). The left and right trigeminal ganglia and the left and right cervical dorsal root ganglia (Cll, CIII, and Cl V pooled for each side) were explanted and incubated independently. The ganglia were then tested for infectious virus after 5 days of incubation as described above.
Antiviral compounds and treatment regimen. Famciclovir and valaciclovir were synthesized at the laboratory of SmithKline Beecham (Brentford, UK) following published methods [14, 20] . The activity of acyclovir and penciclovir, which are the active metabolites of valaciclovir and famciclovir, respectively, were measured against HSV-l by a plaque reduction assay in BALB/c 3T3 cells (derived from BALB/c mice). Penciclovir and acyclovir had similar activity; the EDsos ± SD were 0.02 ± 0.01 and 0.01 ± 0.01 j.lg/mL, respectively [21] . In BHK-21 cells (the cell line used to quantify virus in tissue samples), the EDsos ± SD for penciclovir and acyclovir were 0.2 ± 0.1 and 0.03 ± 0.01 j.lg/mL, respectively [16] .
Famciclovir and valaciclovir were dissolved in double-distilled deionized water and supplied ad libitum at I mg/mL in drinking water. Therapy commenced at 18 h or 2, 3, 4, or 5 days after inoculation, with all treatments terminating at 7 P.M. on day 10 after inoculation. The no chemotherapy group contained 80 mice; treatment groups contained 60 mice.
Fresh solutions were provided to each cage daily. Water consumption per cage was recorded every 12 h; mice showed no distaste for the compounds, and the average amount of drugs consumed (day and night) was~100 mg/kg/day. All mice were examined daily for clinical signs; 8 mice per group were weighed daily and the ear pinnae of the same 8 mice/ group were measured daily for swelling. Groups of 3 mice were killed on each of days I, 3, 5, 6, 8, 10, 11, 12, 13 , and 14 after inoculation. The ear pinnae and brainstems were titrated for infectious virus. Left dorsal root and trigeminal ganglia were tested on day 8 for infectious virus, and both left and right ganglia were explanted between days 106 and 144 after inoculation to reactivate latent virus. The experimental design is summarized in figure I .
A second group of 60 mice were similarly inoculated with virus. These were untreated during the acute phase. Three mice were examined at days 3, 5, and 8 after inoculation to establish that the acute infection was normal. At 3 months after inoculation, groups of mice were given valaciclovir or famciclovir in the drinking water at I mg/mL continuously for 2 weeks; 1 group was given no treatment. After a further period of 2 weeks, groups of 10 mice were killed, and their left and right trigeminal and dorsal root ganglia were explanted and tested for infectious virus as above.
Results
Clinical signs. In the absence of treatment, all mice developed erythematous ears, of which 73% had visible lesions. Although neither famciclovir or valaciclovir affected erythema, famciclovir was markedly superior to valaciclovir in reducing the incidence oflesions (table 1) . Both compounds had a minimal effect on ear paralysis, except when therapy commenced on day 1 after inoculation. However, both did prevent the occurrence of other neurologic signs, except when valaciclovir treatment was delayed until day 5 after inoculation (table 1) .
Mortality. The mortality rate in the control (untreated) group was 27%, with mice dying between days 7 and 9 after inoculation. The mortality in the valaciclovir-treated groups decreased in relation to the time of onset of therapy (figure 2), and all mice survived only when treatment with valaciclovir was commenced on day 2 after inoculation or earlier. The time to death was similar for valaciclovir-treated mice and for those that died without chemotherapy. No mice died in any of the groups treated with famciclovir, even when the onset of therapy was delayed to day 5 after inoculation.
Weight gain. Valaciclovir therapy had no obvious effect on restoring weight gain, and all groups resembled the infected controls. In contrast, famciclovir therapy produced a rapid restoration of weight gain to the uninfected control values within 1 day of commencement of therapy (figure 3). The reversion of weight gain to control values occurred in all groups, including mice in which treatment was withheld until 5 days after inoculation. This is a reproducible observation, and similar rapid restoration of weight on commencement of famciclovir therapy has been observed in previous experiments. The divergences of the treatment curves from the positive and negative controls were significant (Student's t test).
Viral growth in the ear. Titers of infectious virus in control (untreated) mice peaked at day 3 after inoculation, and virus was cleared naturally to undetectable levels by day 10. Valaci- Ear and brain stem samples tested for infectious virus (n=3) Clinical signs were noted daily (n=8)
Ganglia tested for infectious virus (n=8)
clovir and famciclovir therapy from day I after inoculation reduced the area under the curve to 38% and 50% of control value, respectively (figure 4). Relatively small reductions in the growth of virus in the ear were observed with either drug when therapy was commenced at later times.
Viral growth in the brainstem. In untreated mice, virus was first detected in the central nervous system (CNS) at day 5 after inoculation (figure 5). Valaciclovir therapy reduced viral replication to undetectable levels when therapy was commenced at day I after inoculation. In all other groups, substantial titers of virus (10 3 _10 4 pfu/brainstem) were observed between days 5 and 8 after inoculation. Furthermore, in all groups ofmice, a recurrence of infectious virus occurred after cessation I to 3 days after cessation of therapy. In all cases, however, the effect was transitory and subsequent tissue samples were uniformly negative. The suppressive effect of famciclovir on viral replication in the brainstem was more marked than that of valaciclovir; no infectious virus was detected in the brainstems of groups of 3 mice tested after famciclovir treatment from days I, 2, or 3 after inoculation. Low levels of virus (< 10 2 pfu/brainstem) were present when treatment commenced at day 4; when treatment was delayed to day 5 after inoculation, virus titers did not vary markedly from those of untreated controls (area under the curve, 67% of control value). No late recurrence of infectious virus in the brainstem was observed in any mouse after cessation of famciclovir therapy, even when the start of therapy was delayed until day 5 after inoculation. Infection of ganglia during the acute phase. The left trigeminal and the pooled left dorsal root ganglia were tested for the presence of virus at day 8 after inoculation during chemotherapy (table 2) . Contralateral ganglia were not tested. The explanted ganglia were incubated for 5 days before testing for infectious virus; thus, the results for virus isolation were not quantitative, and the ganglia were scored as plus or minus. Results showed that all untreated mice yielded infectious virus from both ganglion samples. All valaciclovir-treatment groups (each containing 8 mice) scored positive in all mice except the group in which therapy was commenced on day I after inoculation. In this group, none of the explanted ganglia from 8 mice yielded virus (table 2). The brainstem was also negative for virus on day 8 after inoculation (cf. figure 5, lower right) . In the groups treated with famciclovir, no virus was detected in ganglia from groups treated from day 1, 2, or 3 after inocula- tion, but all mice scored positive in the groups in which treatment was withheld until day 4 or 5 after inoculation. Of note, among the 11 groups of 8 mice tested at day 8, all mice in each group scored positive or all were negative; no groups yielded mixed results. Reactivation ofvirusfrom latently infected ganglia. During the 3-4 months after inoculation, 16 mice from each treatment group were tested for their ability to yield virus after explantation of the ganglia and incubation for 5 days to allow reactivation to occur. In these mice, both contralateral and ipsilateral ganglia were examined. The trigeminal and pooled cervical dorsal root ganglia were tested separately. A marked difference was seen between the two drugs (table 2, table 3 ). For valaciclovir, all groups yielded reactivated virus from the ipsilateral ganglia. In the case of the contralateral ganglia, no virus was isolated from groups treated from days I or 2 after inoculation.
There was close correlation between trigeminal and dorsal root ganglia from individual mice. For famciclovir therapy, the results were even more striking: No virus was reactivated from any ganglia of any mice in which therapy was commenced at day 3 after inoculation or earlier. When therapy was commenced at day 4 or day 5 after inoculation, virus was detected in the ipsilateral ganglia (although 13% and 38% were positive for treatment begun on days 4 and 5, respectively, compared with 100% for untreated controls).
Furthermore, no virus was reactivated from any contralateral ganglia from any mice that had been treated with famciclovir, including those groups of mice in which treatment did not commence until 5 days after inoculation.
Chemotherapy of latently infected survivors. A separate group of 60 mice were inoculated with a similar dose of virus; no chemotherapy was administered during the acute infection. Clinical signs were noted during the first 2 weeks, and 3 mice were tested for infectious virus in the ear pinnae and brainstems on days 3, 5, and 8 after inoculation. These results were closely similar to those obtained in the first experiment (data not shown). Nine mice died during the acute phase, leaving 51 survivors (minus the 9 mice that had been sampled). At 3 months after inoculation, 3 groups of 10 survivors were treated for 2 weeks with valaciclovir or famciclovir in the drinking water while 1 group remained untreated. Two weeks after completion of treatment (4 months after inoculation), all mice were killed and their ganglia explanted as above. All control mice carried latent infection in the ipsilateral ganglia and, as before, some contralateral ganglia were also positive by this test. Treatment with either drug had no effect on the ability to reactivate infectious virus from the ganglia (ipsilateral or contralateral), and there was no difference between the treatment groups and the untreated controls in this respect (table 4) .
Discussion
Three important points emerged from this study. First, both famciclovir and valaciclovir were effective in preventing disease progression when chemotherapy was started 1 day after inoculation, although valaciclovir was much less effective than famciclovir when therapy was started several days later. Second, after valaciclovir therapy, there was a reproducible recurrence of viral replication in the brainstem samples; in contrast, famciclovir consistently suppressed viral replication during therapy with no recurrence afterwards. Finally, the most important and novel finding emerged from the examination of the reactivation of virus from ganglion explants taken 3-4 months after therapy. Our results suggest that the viral process to establish HSV-1 latency takes~4-5 days to complete, far longer than previously indicated in studies with acyclovir. The nucleoside analogue prodrugs famciclovir and va1acic1ovir provide us with biochemical tools to investigate this process. The superior efficacy of famciclovir relative to valaciclovir confirmed an earlier study in which mice were immunosuppressed during infection [17] . By comparison with the earlier study, it appears that both compounds are less effective in normal, immunocompetent, mice than in immunosuppressed mice. This is likely to be due to the greater inflammatory responses to infection in normal mice, including the release of inflammatory mediators into the site of the infection and, in addition, the release of naturally occurring nucleosides from monocyte/macrophages, including deoxythymidine. These would be expected to hamper the effects of the antiviral nucleoside analogues in vivo. However, famciclovir might be less affected than valaciclovir, since acyclovir has been shown to be more susceptible than penciclovir to antagonism by exogenous deoxythymidine [22] .
Second, although valacicIovir therapy reduced titers of infectious virus in the CNS to below the level of detection, there was a reproducible recurrence of infectious virus after chemotherapy was terminated. It was notable that recurrence occurred later than the time by which surviving control mice had cleared virus naturally from CNS tissue to undetectable levels. This repeats the observations made in two previous studies [16, 17] ; however, in the previous experiments the mice were also immunosuppressed. A recurrence of infectious virus in the ear was also reported in a much older study using acyclovir in immunocompetent mice [4] , and the present experiment demonstrates unequivocally that the phenomenon occurs in mice without immunosuppression. However, recurrences were confined to the CNS, whereas previously in mice that were immunosuppressed, recurrence occurred both in the CNS and in the local tissue at the inoculation site (the ear pinna). However, the lack ofrecurrence in local tissue may be a result of continual drug administration (via the drinking water), since recurrence of viral replication has been observed in the ears of normal mice after cessation of discrete valaciclovir therapy [16] .
The explanation for the differences in efficacies of famciclovir and valaciclovir against acute disease is not clear. Although famciclovir and valaciclovir generated very similar blood concentration-time curves for their respective products, penciclovir and acyclovir, there are as yet no data on the rela- tive distribution of the products to the murine CNS via the blood-brain barrier. However, antiviral potency in murine cells and differences in the bioavailability of penciclovir and acyclovir have been excluded previously [16] . Moreover, similar results were found when famciclovir and valaciclovir were administered by discrete oral gavage [23] , confirming that the difference between the two compounds is not dependent on continual dosing. Previous work showed that recurrence occurs on termination of valaciclovir therapy that has been continued for 5 or 10 days starting from I day after inoculation [16] , but no data are available for longer periods of treatment; it will be important to see whether the phenomenon occurs after more protracted therapy, for example, for 15 or 20 days. Preliminary data with HSV-2 has shown that a recurrence of infectious virus in the peripheral nervous system does occur after therapy with valaciclovir but not with famciclovir (unpublished data). Finally, the most important observations to emerge from the study concerned the reactivation potential of ganglion explants from treated mice. The current belief is that the establishment of latency can be affected only if antiviral therapy starts at or very shortly after the time of infection. Our data clearly show that this is not necessarily the case. Starting famciclovir treatment even 5 days after infection markedly reduced the establishment of a viable latent infection. In addition, our results clearly demonstrated a marked difference between famciclovir and valaciclovir in this respect. Of the mice that had been treated with famciclovir during acute infection, very few had virus reactivation from their ganglia explanted 3-4 months later. This confirms and extends the results of several smaller preliminary experiments. The strength of the present study lies in the very large group sizes used such that 240 mice were tested for latency in this part of the experiment. The results show that virus could not readily be reactivated from ganglia removed from mice in which there had undoubtedly been acute viral replication in the nervous system during the first few days after infection. Furthermore, no virus was reactivated from contralateral ganglia. By contrast, all groups of mice that had been treated with valaciclovir had reactivated virus from at least some ganglia.
Furthermore, we confirmed earlier findings [6, [9] [10] [11] that in mice in which latency was well-established (3 months after infection), a 2-week period of chemotherapy had no measurable effect on the ability of explanted ganglia to reactivate virus. This confirms that fully established latency is different in some critical way from the latency still being established in the ganglia during the first 1-5 days after inoculation. At present, the mechanism that underlies the differences between famciclovir and valaciclovir is unclear, but any hypothesis must take into account at least three factors. First, the intracellular mode of action ofpenciclovir and acyclovir differs in a substantial manner. Second, there is the potential for the compound to cause an effect in the ganglia after infection but before the latent state is fully established. This work is the first demonstration, to our knowledge, that this process takes~4-5 days, far longer than previously assumed from work with acyclovir. Third, the drug-modified latent state has either lost, or has much reduced, its ability to reactivate to give infectious virus. One factor may be that famciclovir has shown greater efficacy in preventing virus reaching or replicating in the brainstem (or both). It is therefore possible that simply a quantitative reduction in the number of latently infected neurons underlies the observations. However, it is possible that sufficient virus has reached the ipsilateral ganglia by day 3 after inoculation to initiate a latent infection. Viral thymidine kinase may possibly be a key factor. Penciclovir has a much higher affinity than acyclovir for the HSV-1 thymidine kinase (K, 1.5 and 173 11M, respectively) [24] . This work proves that famciclovir treatment, starting from 1 to 4 or 5 days after inoculation, can alter the latent state. Thymidine kinase-negative strains of HSV-l are capable of establishing latent infections but have reduced ability to reactivate [25] . The concept that an antiviral compound and thymidine kinase inhibitor may give synergistic inhibition of reactivation from latency has been reported recently [26] . Further work to explore these possibilities is in progress, including investigations at the molecular level, which are currently underway. Preliminary results suggest that there is no obvious difference between the two compounds in the number of ganglionic cells that stain positive for latency-associated transcripts. However, the role oflatency-associated transcriptpositive cells in latency is controversial, and in situ polymerase chain reaction has suggested that more cells may contain HSV DNA than express latency-associated transcripts [27] [28] [29] ; it remains uncertain which cells are most important in reactivation.
Whatever the explanation for the observations in this study, chemotherapy with famciclovir but not valaciclovir during the primary infection, in the mouse at least, affects the subsequent latent infection. Furthermore, the importance of the recurrence of infection in the CNS on cessation of valaciclovir remains to be established. For example, it should be determined whether it is peculiar to the murine ear pinna model or whether it may also apply in different infection models. Recent observations have confirmed that similar results occur with HSV-2 in this model (unpublished data). Whether these results can be extrap-olated to humans is at present uncertain but could have interesting implications. We have shown that there is a "window of opportunity" for therapy between the initiation and establishment of a viable latent infection. Early treatment of the primary disease could be expected to lead to a subsequent decrease in recurrent disease.
In summary, this is the first time that late-onset antiviral therapy has been shown to affect the subsequent ability of latent HSV to reactivate. The differential effect between famciclovir and valaciclovir may prove to be a useful tool for investigating the process of establishment of latency.
